CA
KROS icon

Clearstead Advisors’s Keros Therapeutics KROS Stock Holding History

Clearstead Advisors’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.21K Buy
+113
New +$1.26K ﹤0.01% 2635
2026
Q1 		– Sell
-3
Closed -$62 – 2579
2025
Q4 		$62 Sell
3
-197
-99% -$3.46K ﹤0.01% 2583
2025
Q3 		$3.16K Buy
200
+81
+68% +$1.2K ﹤0.01% 2321
2025
Q2 		$1.59K Buy
+119
New +$1.61K ﹤0.01% 2373

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Clearstead Advisors's KROS Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Keros Therapeutics (KROS) in Q2 2026: 113 shares worth $1.21K. The stake represents ﹤0.01% of the portfolio and ranks #2635 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in KROS as recently as Q4 2025.

Clearstead Advisors first reported a position in KROS in Q2 2025 and has held it in 4 quarters since. The position peaked at $3.16K in Q3 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Clearstead Advisors held 113 shares of Keros Therapeutics worth $1.21K as of Q2 2026.
  • Keros Therapeutics was a new Clearstead Advisors position in Q2 2026.
  • Keros Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2635 holding.
  • Clearstead Advisors first reported a position in Keros Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Clearstead Advisors's Keros Therapeutics position peaked at $3.16K in Q3 2025.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.